checkAd

SPECTRUM ALERT Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) on behalf of Spectrum stockholders. Our investigation concerns whether Spectrum has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On September 22, 2022, Reuters reported that advisers to the U.S Food and Drug Administration “voted against recommending Spectrum Pharmaceuticals’ experimental drug for the treatment of patients with a form of non-small cell lung cancer. The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization. The panel’s decision was in-line with briefing documents released by the drug regulator on Tuesday that raised concerns over the efficacy of the treatment compared with existing drugs like Daiichi Sankyo’s 4568.T AstraZeneca’s Enhertu.”

On this news, Spectrum’s stock price fell $0.207 per share, or 32.65%, to close at $0.427 per share on September 23, 2022.

If you purchased or otherwise acquired Spectrum shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.


The Spectrum Pharmaceuticals Stock currently trades with a fall of -5,80 % to 0,450EUR on the Tradegate stock exchange.

Nachrichtenquelle: Business Wire (engl.)
 |  105   |   |   

Schreibe Deinen Kommentar

Disclaimer

SPECTRUM ALERT Bragar Eagel & Squire, P.C. is Investigating Spectrum Pharmaceuticals, Inc. on Behalf of Spectrum Stockholders and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (NASDAQ: SPPI) on behalf of Spectrum stockholders. Our …

Nachrichten des Autors

103 Leser
100 Leser
77 Leser
64 Leser
52 Leser
39 Leser
23 Leser
18 Leser
17 Leser
17 Leser
443 Leser
329 Leser
200 Leser
187 Leser
173 Leser
161 Leser
154 Leser
148 Leser
146 Leser
140 Leser
1142 Leser
745 Leser
589 Leser
515 Leser
498 Leser
475 Leser
463 Leser
443 Leser
411 Leser
398 Leser
7528 Leser
2918 Leser
2428 Leser
2378 Leser
2155 Leser
2102 Leser
1787 Leser
1699 Leser
1586 Leser
1533 Leser